Human Health: Our expertise includes therapeutics, vaccines, medical devices, clinical diagnostics and emerging cell and gene therapy applications
In depth sector knowledge
Our human health team have career backgrounds that include in- and out-licensing, business development, research and academic liaison positions within multinational companies such as AstraZeneca, GSK, Roche, Charles River and Eli Lilly, as well as individuals who have worked within university technology transfer offices, healthcare-focussed venture capital and a university seed fund.
Broad technology and development stage experience
We work with technology opportunities across the clinical development pathway from discovery through to late-stage clinical candidates. Clients leverage our extensive market intelligence built from previous projects, our subscription databases, attendance at global industry events and through our personal industry networks.
Global reach
We maintain extensive contacts globally across the pharma and biotech sector. We have experienced staff with pharma backgrounds based in London, Edinburgh, New York and Sydney with access to local markets for market intelligence and partnering.
Industry Sector Lead:
Ronnie Georghiou
Executive Director
+44 (0)203 735 7651
ronnie.georghiou@ip-pragmatics.com
Recent Projects
- Valuation of the royalty stream due to a UK-based research organisation arising from sales of a blockbuster drug by their licensee.
- Supporting a dual NASDAQ and ASX-listed gene therapy SME with business development and IP intelligence support.
- Leading business development and term sheet negotiations with a NASDAQ listed company on behalf of a clinical diagnostics SME.
Recent Projects
- Developing and implementing a partnering strategy for novel CAR-T allogeneic therapy.
- Pathfinder for a novel GPCR drug discovery platform.
- Defining the value proposition for a novel, virtual polymorph screening and prediction service offering.
- Scouting for potential partners for a novel small molecule therapeutic.
- Competitive analysis of pharma pipelines in the fields of immunology, neurosciences, oncology and immunology.
Recent Projects
- Portfolio review and ranking of early stage pipeline assets in the therapeutic fields of diabetes, inflammation, CNS, diagnostics biomarkers and tools and cell lines for drug discovery.
- Scouting for novel disinfection technologies on behalf of a publicly-listed multinational medical device company.
- Evaluating gene therapy opportunities in the fields of muscular dystrophy, macular degeneration and hepatitis B.
- Partnering support for a technology that enhances the manufacture of biological therapeutics.
- Defining the market entry strategy into advanced cell therapies supply chain.
Project Outcomes
- Leading contract negotiations on behalf of big pharma clients under the Innovative Medicine’s Initiative for 20 IMI projects valued at €5-10 million each.
- Multiyear contract to advise on operations and the strategic growth of a market access company focussed on rare and severe disease medicines for mid- and large-pharma clients, that has almost doubled in size in this period.
- Supporting the development of a business plan and start-up of a pharma SME as part of a significant fund raising round and appointed to advise on a subsequent Ph2a Proof-of-Concept clinical trial after the successful funding round.
- Undertaking valuations for a meningitis B vaccine clinical phase candidate and a respiratory syncytial virus pre-clinical vaccine candidate for a Dutch government institute, including providing business development support to help the client complete a major joint development and licensing agreement.
